mptp

MPTP hydrochloride is a dopamine neurotoxin and the precursor of MPP⁺. It can induce apoptosis and has the ability to cross the blood-brain barrier. MPTP hydrochloride is toxic to dopaminergic neurons and is commonly used for the construction of Parkinson's disease animal models.

mPTP-IN-22 is a novel mitochondrial permeability transition pore (mptp) inhibitor

MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a dopamine neurotoxin capable of crossing the blood-brain barrier, often employed to induce models of Parkinson's syndrome. As a precursor to MPP+, MPTP can trigger apoptosis (apoptosis).

ER-000444793 is a potent mitochondrial permeability transition pore (mPTP) opening inhibitor and it also inhibits mPTP (IC50: 2.8 μM).

Jak2-IN-7j is a selective Jak2 inhibitor which demonstrates a time-dependent knock-down of pSTAT5, which is a downstream target of Jak2.

mPTP-IN-1 (Compound 14e) is an inhibitor of the mitochondrial permeability transition pore (mPTP). By targeting the C subunit of ATP synthase, mPTP-IN-1 prevents calcium-induced opening of the mPTP. This compound is applicable in studies related to myocardial ischemia/reperfusion injury (IRI).

LMPTP Inhibitor 1 Dihydrochloride is a compound selectively targeting low molecular weight protein tyrosine phosphatase (LMPTP), exhibiting potent inhibitory activity with an IC50 value of 0.8 μM for LMPTP-A.

LMPTP INHIBITOR 1 hydrochloride is a selective inhibitor of low molecular weight protein tyrosine phosphatase (LMPTP), with an IC50 of 0.8 μM for LMPTP-A.

MptpB-IN-1 is a potent, orally active MptpB inhibitor that targets the Mycobacterium tuberculosis protein-tyrosine-phosphatase B (MptpB), a secreted virulence factor evading host antimicrobial mechanisms. It effectively diminishes the survival and infection burden of multidrug-resistant Mycobacterium tuberculosis.

MptpB-IN-2 (compound 20), a selective inhibitor for mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB), exhibits half maximal inhibitory concentrations (IC50) of 0.64 μM for MptpB, 4.06 μM for MptpA, and 4.14 μM for PTP1B. Despite its inhibition potency, MptpB-IN-2 demonstrates limited antituberculosis efficacy, with a minimum inhibitory concentration (MIC) of 64.9 μM against Mtb H37Rv [1].

Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability. vutiglabridin ameliorates mptp-induced neurodegeneration in Parkinson's disease mice by targeting mitochondrial paraoxonase-2. Vutiglabridin is a clinical phase 2 drug for the treatment of obesity and has therapeutic effects on p-mitochondrial PON2 in a PD model. vutiglabridin penetrates the brain, binds PON2, and restores 1-methyl-4-phenylpyridine (MPP*)-induced neuroblastoma in SH-SY5Y Vutiglabridin significantly attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dyskinesia and dopaminergic neuronal damage in mice modeled with PD in mouse experiments.

ML400 (CID73050863) is an allosteric inhibitor of LMPTP with an EC50 of 1μM. ML400 displays good cell-based activity and rodent pharmacokinetics.

Cefsulodin sodium (Sulcephalosporin) hydrate is a β lactam antibiotic.

MDK-4823, also known as LMPTP inhibitor1, is a potent low-molecular-weight tyrosine phosphatase (LMPTP) inhibitor. LMPTP is highly expressed in insulin-target tissues. LMPTP promotes diabetes and insulin resistance in obesity.

1. Ginkgetin has anti-influenza virus and anti-fungal activities. 2. Ginkgetin has anti-inflammatory activity, can down-regulates COX-2 induction in vivo against skin inflammatory responses. 3. Ginkgetin is a good STAT3 inhibitor and may be a useful lead

AV-101 (4-Cl-KYN) , a prodrug antagonist at the glycine site of the NMDA receptor, has antidepressant activity and reduces levodopa-induced dyskinesia in MPTP monkeys.

Fenlean (FLZ) is a tyrosine kinase Src inhibitor, a synthetic cyclic derivative of squamous amide from Annona glabra, with cytoprotective activity, which protects tyrosine hydroxylase function in a chronic MPTP/prostaglandin-type mouse model of Parkinson's disease.Fenlean inhibits the production of Aβ in the mitochondria, which may be useful in the study of age-related macular degeneration and Parkinson's disease. and Parkinson's.

MPP+ iodide, the metabolite of a neurotoxin MPTP, causes symptom of Parkinson's disease (PD) in animal models by selectively destroying dopaminergic neurons in substantia nigra. MPP+ induces dopamine transporter (DAT) externalization in dopaminergic (DA) neurons, but internalization of serotonin transporter (SERT) in serotonergic (5-HT) neurons. MPP+ induces autophagic cell death in SH-SY5Y cells.

ATP synthase inhibitor 1 is an inhibitor of the c subunit of the F1/FO-ATP synthase complex. It inhibits mitochondrial permeability transition pore (mPTP) opening and does not affect ATP levels.

hMAO-B-IN-10 (compound 7) is an inhibitor of MAO-A/B with IC50 values of 424.1 nM and 177.9 nM, respectively. It has demonstrated neuroprotective effects in the MPTP-induced mouse model of Parkinson's Disease (PD).

NPC26 is a small molecule that disrupts mitochondrial function and exhibits antitumor activity. It shows significant antiproliferative and cytotoxic effects on CRC cell lines (HCT-116, DLD-1, and HT-29). NPC26 induces mitochondrial permeability transition pore (mPTP) opening, generates reactive oxygen species (ROS), and triggers cell death. Additionally, NPC26 kills CRC cells by activating the AMP-activated protein kinase (AMPK) signaling pathway.

A-86929 is a potent and selective dopamine D1 receptor agonist with a pKi of 7.3. It significantly induces rotational behavior in a 6-OHDA-induced unilateral nigral lesion rat model and improves motor function in an MPTP-induced Parkinson's disease marmoset model. Furthermore, A-86929 shows potential value in reducing cocaine-induced craving behavior in rats and reversing Haloperidol-induced cognitive deficits in rhesus monkeys. The compound is useful for researching neurological disorders.

C105SR is a cyclophilin D (CypD) inhibitor targeting peptidyl-prolyl cis-trans isomerase (PPIase). It has an IC50 value of 5 nM for inhibiting mitochondrial permeability transition pore (mPTP) opening. C105SR reduces apoptosis in hepatocytes induced by hypoxia-reoxygenation and boosts calcium retention capacity (CRC). It demonstrates hepatoprotective effects in a mouse model of ischemia-reperfusion injury (IRI).

HPTP is a monoaminergic neurotoxin related to MPTP. It is the dehydration product of haloperidol. The agent is specifically a dopaminergic and serotonergic neurotoxin. HPTP is a prodrug of HPP+, which mediates its monoaminergic neurotoxicity, HPTP can be utilized for building neurotoxic or immuno-deficient model for research related to neuroscience.